A new treatment for polyarteritis nodosa

Wu, Kenneth W.; Throssell, David

doi:10.1093/ndt/gfk082

Cited by 19 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other maintenance agents include methotrexate, mycophenolate mofetil and cyclosporin A [82]. Adjunctive plasma exchange can be used in life-threatening situations [83, 84], and more recently, successful treatment with biologic agents such as infliximab or rituximab has been reported for those unresponsive to conventional therapy [24, 80–82, 85–88]. Treatment response can be assessed using a modified Birmingham Vasculitis Activity Score [82].…”

Section: Polyarteritis Nodosamentioning

confidence: 99%

Medium-size-vessel vasculitis

Dillon¹,

Eleftheriou²,

Brogan³

2009

Pediatr Nephrol

107

View full text Add to dashboard Cite

Medium-size-artery vasculitides do occur in childhood and manifest, in the main, as polyarteritis nodosa (PAN), cutaneous PAN and Kawasaki disease. Of these, PAN is the most serious, with high morbidity and not inconsequential mortality rates. New classification criteria for PAN have been validated that will have value in epidemiological studies and clinical trials. Renal involvement is common and recent therapeutic advances may result in improved treatment options. Cutaneous PAN is a milder disease characterised by periodic exacerbations and often associated with streptococcal infection. There is controversy as to whether this is a separate entity or part of the systemic PAN spectrum. Kawasaki disease is an acute self-limiting systemic vasculitis, the second commonest vasculitis in childhood and the commonest cause of childhood-acquired heart disease. Renal manifestations occur and include tubulointerstitial nephritis and renal failure. An infectious trigger and a genetic predisposition seem likely. Intravenous immunoglobulin (IV-Ig) and aspirin are effective therapeutically, but in resistant cases, either steroid or infliximab have a role. Greater understanding of the pathogenetic mechanisms involved in these three types of vasculitis and better long-term follow-up data will lead to improved therapy and prediction of prognosis.

show abstract

Section: Polyarteritis Nodosamentioning

confidence: 99%

Medium-size-vessel vasculitis

Dillon¹,

Eleftheriou²,

Brogan³

2009

Pediatr Nephrol

107

View full text Add to dashboard Cite

show abstract

“…Standard treatment with corticosteroids and cyclophosphamide has drammatically improved the prognosis but medication induced morbidity is frequent. The successful use of anti TNF therapy in treating adult and chilhood systemic or cutaneous PAN has been reported in several papers (Al- Bishri J et al, 2005;Brik R et al, 2007;de Kort AWK et al, 2006;Feinstein J et al,2005;Garcia-Porrua et al, 2003;Vega Gutierrez J et al, 2007;Wahezi DM et al, 2010;Wu K et al, 2006) The largest study sample was conducted over three years and examined 11 young patients treated with TNF α inhibitors, 8 with Infliximab, (2 later changed the therapy to Adalimumab and Rituximab) and 3 patients were treated with Etanercept The dosage of Infliximab given to patients varied from 3 to 6 mg/Kg and a dose of 0.8 mg/Kg for Etanercept. Side effects appeared in three patients: a staphylococcus epidermidis sepsis and cerebral abscesses following Infliximab therapy and a bowel perforation a month after starting Etanercept.…”

Section: Polyarteritis Nodosamentioning

confidence: 97%

Biologic Agents for the Treatment of Systemic Vasculitis

Sfriso¹,

Schiavon²

2011

Advances in the Diagnosis and Treatment of Vasculitis

View full text Add to dashboard Cite

“…In PAN, infliximab has been used in refractory forms of the disease or because of intolerance to conventional drugs and seems to be effective [48]. In a small case series, nine refractory PAN patients were treated with infliximab and 8 of 9 patients (89%) achieved significant improvement and prednisone dose reduction of 50% [49].…”

Section: Tumor Necrosis Factor (Tnf) α Inhibitormentioning

confidence: 99%

Vasculitis: From Target Molecules to Novel Therapeutic Approaches

Chung

2021

Biomedicines

View full text Add to dashboard Cite

Systemic vasculitis is a group of diverse diseases characterized by immune-mediated inflammation of blood vessels. Current treatments for vasculitis, such as glucocorticoids and alkylating agents, are associated with significant side effects. In addition, the management of both small and large vessel vasculitis is challenging due to a lack of robust markers of disease activity. Recent research has advanced our understanding of the pathogenesis of both small and large vessel vasculitis, and this has led to the development of novel biologic therapies capable of targeting key cytokine and cellular effectors of the inflammatory cascade. It is anticipated that these novel treatments will lead to more effective and less toxic treatment regimens for patients with systemic vasculitis.

show abstract

A new treatment for polyarteritis nodosa

Cited by 19 publications

References 4 publications

Medium-size-vessel vasculitis

Medium-size-vessel vasculitis

Biologic Agents for the Treatment of Systemic Vasculitis

Vasculitis: From Target Molecules to Novel Therapeutic Approaches

Contact Info

Product

Resources

About